Ib Acquisition CORP 8-K filings

IB Acquisition Corp. has extended its deadline to complete an initial business combination by six months to September 28, 2026, following stockholder approval.

IB Acquisition Corp. stockholders approved an extension for its business combination deadline until September 28, 2026, amidst significant share redemptions.

IB Acquisition Corp. and GNQ Insilico Inc. announced a joint initiative with a Fortune 100 global technology company to advance AI-driven drug discovery and precision medicine.

GNQ Insilico, an AI-powered drug development company, announced its plan to go public through a business combination with SPAC IB Acquisition Corp., valuing GNQ at $500 million.

IB Acquisition Corp. stockholders approved an extension for its business combination deadline to March 28, 2026, following significant share redemptions.

IB Acquisition Corp. has dismissed UHY LLP as its independent auditor and appointed MaloneBailey LLP, effective April 22, 2024 and April 24, 2024 respectively.

IB Acquisition Corp. will separate its units into common stock and rights, which will begin trading separately on the Nasdaq Capital Market on May 1, 2024.

IB Acquisition Corp. has dismissed UHY LLP as its independent auditor and appointed MaloneBailey LLP, effective April 22, 2024.

IB Acquisition Corp. successfully closed its initial public offering, raising $115 million to pursue a business combination.

IB Acquisition Corp. successfully closed its initial public offering, raising $115 million after fully exercising the underwriters' over-allotment option.